Merve Uça Apaydin

Dr. Merve Uça Apaydin


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2021 in Materials
Verified
Journal Article
Open access
PDF file
MAMerve Uça Apaydin
Merve Uça Apaydin
EEEce Eksin
Ece Eksin
YEYasemin Eraç
Yasemin Eraç
AEArzum Erdem
Arzum Erdem
Hydroxyapatite nanoparticles (HaP) and ionic liquid (IL) modified pencil graphite electrodes (PGEs) are newly developed in this assay. Electrochemical impedance spectroscopy (EIS), scanning electron microscopy (SEM), energy-dispersive X-ray spectroscopy (EDX), and cyclic voltammetry (CV) were applied to examine the microscopic and electrochemical characterization of HaP and IL-modified biosensors. The interaction of curcumin with nucleic acids and polymerase chain reaction (PCR) samples was investigated by measuring the changes at the oxidation signals of both curcumin and guanine by differential pulse voltammetry (DPV) technique. The optimization of curcumin concentration, DNA concentration, and the interaction time was performed. The interaction of curcumin with PCR samples was also investigated by gel electrophoresis.

17 December 2023 in Genes
Verified
Journal Article
Open access
PDF file
SVSpyridon N. Vasilopoulos
Spyridon N. Vasilopoulos
HGHüseyin Güner
Hüseyin Güner
MAMerve Uça Apaydin
Merve Uça Apaydin
APAthanasia Pavlopoulou
Athanasia Pavlopoulou
ALEXANDROS GEORGAKILASALEXANDROS GEORGAKILAS
ALEXANDROS GEORGAKILAS
Ionizing radiation can induce different types of DNA lesions, leading to genomic instability and ultimately cell death. Radiation therapy or radiotherapy, a major modality in cancer treatment, harnesses the genotoxic potential of radiation to target and destroy cancer cells. Nevertheless, cancer cells have the capacity to develop resistance to radiation treatment (radioresistance), which poses a major obstacle in the effective management of cancer. It has been shown that administration of platinum-based drugs to cancer patients can increase tumor radiosensitivity, but despite this, it is associated with severe adverse effects. Several lines of evidence support that activation of the DNA damage response and repair machinery in the irradiated cancer cells enhances radioresistance and cellular survival through the efficient repair of DNA lesions. Therefore, targeting of key DNA damage repair factors would render cancer cells vulnerable to the irradiation effects, increase cancer cell killing, and reduce the risk of side effects on healthy tissue. Herein, we have employed a computer-aided drug design approach for generating ab initio a chemical compound with drug-like properties potentially targeting two proteins implicated in multiple DNA repair pathways. The findings of this study could be taken into consideration in clinical decision-making in terms of co-administering radiation with DNA damage repair factor-based drugs.

Verified
Journal Article
Open access
PDF file
SGStyliani Geronikolou
Styliani Geronikolou
APAthanasia Pavlopoulou
Athanasia Pavlopoulou
MAMerve Uça Apaydin
Merve Uça Apaydin
KAKonstantinos Albanopoulos
Konstantinos Albanopoulos
DCDennis V Cokkinos
Dennis V Cokkinos
GCGeorge Chrousos
George Chrousos
Obesity, a chronic, preventable disease, has significant comorbidities that are associated with a great human and financial cost for society. The aim of the present work is to reconstruct the interactomes of non-hereditary obesity to highlight recent advances of its pathogenesis, and discover potential therapeutic targets. Obesity and biological-clock-related genes and/or gene products were extracted from the biomedical literature databases PubMed, GeneCards and OMIM. Their interactions were investigated using STRING v11.0 (a database of known and predicted physical and indirect associations among genes/proteins), and a high confidence interaction score of >0.7 was set. We also applied virtual screening to discover natural compounds targeting obesity- and circadian-clock-associated proteins. Two updated and comprehensive interactomes, the (a) stress- and (b) inflammation-induced obesidomes involving 85 and 93 gene/gene products of known and/or predicted interactions with an average node degree of 9.41 and 10.8, respectively, were produced. Moreover, 15 of these were common between the two non-hereditary entities, namely, ADIPOQ, ADRB2/3, CCK, CRH, CXCL8, FOS, GCG, GNRH1, IGF1, INS, LEP, MC4R, NPY and POMC, while phelligridin E, a natural product, may function as a potent FOX1-DBD interaction blocker. Molecular networks may contribute to the understanding of the integrated regulation of energy balance/obesity pathogenesis and may associate chronopharmacology schemes with natural products.

25 October 2024 in Cancers
Verified
Journal Article
Open access
PDF file
SASadaf Asfa
Sadaf Asfa
RBReza Arshinchi Bonab
Reza Arshinchi Bonab
OÖOnur ÖNDER
Onur ÖNDER
MAMerve Uça Apaydin
Merve Uça Apaydin
HDHatice Döşeme
Hatice Döşeme
APAthanasia Pavlopoulou
Athanasia Pavlopoulou
Background/Objectives: Acute myeloid leukemia (AML) is characterized by therapeutic failure and long-term risk for disease relapses. As several therapeutic targets participate in networks, they can rewire to eventually evade single-target drugs. Hence, multi-targeting approaches are considered on the expectation that interference with many different components could synergistically hinder activation of alternative pathways and demolish the network one-off, leading to complete disease remission. Methods: Herein, we established a network-based, computer-aided approach for the rational design of drug combinations and de novo agents that interact with many AML network components simultaneously. Results: A reconstructed AML network guided the selection of suitable protein hubs and corresponding multi-targeting strategies. For proteins responsive to existing drugs, a greedy algorithm identified the minimum amount of compounds targeting the maximum number of hubs. We predicted permissible combinations of amiodarone, artenimol, fostamatinib, ponatinib, procaine, and vismodegib that interfere with 3–8 hubs, and we elucidated the pharmacological mode of action of procaine on DNMT3A. For proteins that do not respond to any approved drugs, namely cyclins A1, D2, and E1, we used structure-based de novo drug design to generate a novel triple-targeting compound of the chemical formula C15H15NO5, with favorable pharmacological and drug-like properties. Conclusions: Overall, by integrating network and structural pharmacology with molecular modeling, we determined two complementary strategies with the potential to annihilate the AML network, one in the form of repurposable drug combinations and the other as a de novo synthesized triple-targeting agent. These target–drug interactions could be prioritized for preclinical and clinical testing toward precision medicine for AML.

30 September 2026 in Cukurova Medical Journal
Verified
Journal Article
Open access
MAMerve Uça Apaydin
Merve Uça Apaydin
HGHüseyin Güner
Hüseyin Güner
RÜReşat Ünal
Reşat Ünal
HPHalil İbrahim Pazarbaşı
Halil İbrahim Pazarbaşı
AGAlexandros G Georgakılas
Alexandros G Georgakılas
APAthanasia Pavlopoulou
Athanasia Pavlopoulou
Purpose: Obesity-associated colorectal cancer (CRC) involves complex molecular networks that limit the effectiveness of single-target therapies. This study aimed to develop an integrative computational pipeline for identifying key regulatory hubs and designing a multi-target-directed ligand (MTDL) capable of simultaneously modulating critical components of the CRC interactome.Materials and Methods: Differential gene expression analysis between CRC and corresponding healthy tissue-derived samples identified upregulated genes in colon adenocarcinoma. A high-confidence protein–protein interaction network was constructed from these genes to identify central hub proteins using topological analysis. To target these hubs, structure-based de novo ligand design and molecular docking were employed to evaluate binding affinities and multi-target potential. Finally, the candidate MTDL underwent in silico pharmacokinetic (ADME) and toxicity profiling, supplemented by a similarity search within natural compound libraries.Results: A total of 786 upregulated genes were identified, of which 204 formed a dense functional interactome. Three central hubs (CDC6, CCNB1, and CDC25C), all critical to cell cycle regulation, were prioritized as therapeutic targets. The designed MTDL demonstrated favorable binding affinities across all targets, interacting with functionally conserved domains. Furthermore, the ligand exhibited a favorable drug-like profile, characterized by high gastrointestinal absorption and a low toxicity risk. Screening of natural product libraries yielded several analogs with comparable binding profiles, supporting the chemical feasibility of the proposed scaffold.Conclusion: This study presents a network-guided framework for multi-target drug design in CRC. By shifting from a "one-target, one-drug" model to a systems-level approach, the proposed MTDL and its natural analogs represent promising candidates for experimental validation in the treatment of complex, obesity-associated CRC.